• Toremifene: A Selective Estrogen-Receptor Modulator for Pros

  2026-08-04

  Toremifene is a second-generation selective estrogen-receptor modulator (SERM) used to interrogate estrogen receptor signaling in hormone-responsive cancer research. Its potent in vitro inhibition of cell growth and well-defined mechanism make it a key tool for dissecting metastatic pathways, especially in prostate cancer. This article reviews atomic evidence, protocol parameters, and critical boundaries for its research use.

• Erastin and Ferroptosis: Mechanistic Insights for Targeted C

  2026-08-04

  Explore how Erastin, a potent ferroptosis inducer, enables advanced cancer biology research by leveraging unique redox vulnerabilities in RAS/BRAF-mutant tumor cells. This article delivers a mechanistic deep dive and practical guidance not found in existing protocol-focused resources.

• Busulfan: DNA Alkylating Agent for Germ Cell Depletion Model

  2026-08-03

  Busulfan enables precision modeling of germ cell depletion and cellular senescence, underpinned by robust DNA alkylation and pathway activation. Recent genetic tracing studies confirm its experimental rigor and clarify its mechanistic boundaries, making it indispensable for reproductive and translational research.

• Optimizing mRNA Delivery with ARCA Cy3 EGFP mRNA (5-moUTP)

  2026-08-03

  ARCA Cy3 EGFP mRNA (5-moUTP) empowers direct, real-time tracking and quantification of mRNA delivery and translation in mammalian cells, combining Cy3 fluorescence with 5-methoxyuridine modification for minimal immune activation. This applied guide details protocol enhancements, troubleshooting strategies, and workflow innovations that set this reagent apart for high-performance mRNA transfection, imaging, and localization studies.

• Multi-Omics Networks Reveal ARID1A-Driven Melanoma Resistanc

  2026-08-02

  This study employs integrative multi-omics to map early and acquired resistance mechanisms in BRAF-mutant melanoma, focusing on ARID1A loss. Its network analysis uncovers key signaling nodes and immune evasion features, informing therapeutic strategies and experimental design for researchers investigating melanoma drug resistance.

• Lyotropic Self-Assembly of Coil-Bottlebrush Diblocks in Ioni

  2026-08-01

  This study demonstrates that coil-bottlebrush diblock copolymers form diverse nanostructured morphologies in alkylimidazolium-based ionic liquids, with network phase formation largely independent of the ionic liquid's alkyl chain length. These findings expand the design flexibility for advanced nanomaterials in ion-rich environments, informing the development of functional membranes and energy devices.

• Tumor-Targeted PAD4 Inhibitors Disrupt NETs to Suppress Meta

  2026-07-31

  This study introduces phenylboronic acid (PBA)-modified PAD4 inhibitors that selectively target the PAD4-H3cit-NETs pathway in neutrophils, demonstrating potent inhibition of tumor growth and metastasis in vivo. The innovative strategy leverages dual tumor targeting and precise modulation of neutrophil nuclear activity, offering new directions for anti-metastatic cancer therapeutics.

• EPZ-6438: EZH2 Inhibitor Workflows in Epigenetic Cancer Rese

  2026-07-31

  EPZ-6438 empowers researchers to dissect PRC2-driven oncogenesis across diverse cancer models with nanomolar precision and workflow flexibility. This guide details experimental design, protocol optimization, and troubleshooting strategies to unlock the full translational potential of this benchmark EZH2 inhibitor.

• Dextrose (D-glucose) in Glucose Metabolism Research: Protoco

  2026-07-30

  Dextrose (D-glucose) from APExBIO empowers high-fidelity glucose metabolism research, addressing critical needs in tumor microenvironment and immune metabolism studies. This guide delivers stepwise experimental workflows, advanced troubleshooting, and actionable parameters for reproducible results in cellular energy and diabetes research.

• NU7441 (KU-57788): Transforming DNA Repair and Oncology Rese

  2026-07-30

  NU7441 (KU-57788) DNA-PK inhibitor empowers precise DNA damage response studies and robust cell cycle modulation, making it an indispensable tool in cancer and DNA repair research. Its nanomolar potency and selectivity streamline experimental workflows and amplify the impact of oncology protocols.

• PF-562271 HCl: Advanced FAK/Pyk2 Inhibition in Cancer Resear

  2026-07-29

  PF-562271 HCl stands out as a highly selective FAK/Pyk2 inhibitor, enabling precise dissection of focal adhesion kinase signaling in tumor biology. This article delivers actionable workflows, troubleshooting guidance, and strategic integration tips for maximizing the compound’s value in tumor growth inhibition and microenvironment studies.

• miR-196a Drives Esophageal Cancer via the c-Myc/TERT/NFκB Ax

  2026-07-29

  This study uncovers how microRNA-196a (miR-196a) enhances the aggressiveness of esophageal adenocarcinoma by activating the c-Myc/TERT/NFκB signaling axis. The mechanistic insights highlight actionable pathways and molecular targets, underscoring the value of c-Myc inhibition in translational cancer research.

• Fucoidan: Applied Workflows and Troubleshooting in Cancer an

  2026-07-28

  Fucoidan stands out as a sulfated α-L-fucan with powerful anticancer and immune-modulating activities, now extended to protecting against chemotherapy-induced liver injury. This article translates breakthrough findings and protocol enhancements into actionable workflows, empowering researchers to maximize reproducibility and biological insight with APExBIO's high-purity Fucoidan.

• Difloxacin HCl: Mechanistic Insights for Precision Antimicro

  2026-07-28

  Explore Difloxacin HCl as a quinolone antimicrobial antibiotic through a mechanistic, protocol-focused lens. This article delves into DNA gyrase inhibition, cross-domain resistance reversal, and actionable assay design insights seldom addressed in existing resources.

• Abiraterone Acetate: Precision CYP17 Inhibition in 3D Prosta

  2026-07-27

  Explore how Abiraterone acetate, a potent CYP17 inhibitor, empowers translational prostate cancer research by enabling precise androgen pathway targeting in advanced 3D spheroid models. This article delivers new insights into assay design, mechanistic selectivity, and protocol optimization for next-generation prostate cancer research.

16071 records 1/1072 page Next 12345 下5页 Last page